Retrophin, Inc. (RTRX)


Stock Price Forecast

Nov. 18, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Retrophin, Inc. chart...

About the Company

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Sector

Health Technology

Industry

Biotechnology

Employees

221

CEO

Eric Dube

Exchange

NASDAQ

Website

http://www.retrophin.com

$194M

Total Revenue

221

Employees

$1B

Market Capitalization

-14.02

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RTRX News

Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook

5d ago, source:

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Travere Therapeutics (TVTX – Research Report). The associated ...

We don't have any news on Retrophin, Inc. at the moment.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...